Trinity Partners: Data Group

Oncology at Trinity Partners

In any therapeutic area, it is important to fully understand a market opportunity in order to make the critical decisions necessary for commercial success. From reimbursement to drug development, to the very sales call itself, this market operates by a "different set of rules."

Our Principals have an average of 12 years of experience working in this therapeutic area. Our clients range from leading pharmaceutical companies and biotechnology companies facing strategic decisions in drug development, licensing, and marketing.

Our approach is to mix our industry expertise with the quantitative focus that is the cornerstone of the Trinity Advantage. Typical services include:

Tumor-specific forecasting and market estimation
Sales and marketing analysis
Clinical development strategies (both registration-based and exploratory)
Reimbursement consulting
Licensing and acquisition support
Evaluation of oncology-specific data sources
Pricing studies

CASE EXAMPLE
Situation   Our client, a late-stage biotechnology company with their first oncology product in Phase III trials, was seeking a licensing partner. They needed a credible and comprehensive product forecast to ensure proper valuation and to provide a basis for negotiation with potential suitors.

Approach   Trinity provided a worldwide forecast based on tumor and indication specific markets. Trinity provided innovative, data-driven analysis on market sizes, pricing, and penetration based on existing and emerging products. The client used the analysis during negotiations to defend their forecast and therefore their valuation. Because of the uncertainties in oncology drug development, Trinity provided a range of scenarios to value individual tumors, refractory or first-line indications, and the impact of publication strategies on trial use by oncologists.

Results   Our client successfully licensed their product to a leading oncology company. This agreement made history as one of the top five deals for an oncology therapeutic, and included potential milestones and equity payments in excess of $400 MM.